Corient Private Wealth LLC Purchases 2,097 Shares of Boston Scientific Co. (NYSE:BSX)

Corient Private Wealth LLC boosted its stake in shares of Boston Scientific Co. (NYSE:BSX) by 1.2% in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 170,536 shares of the medical equipment provider’s stock after buying an additional 2,097 shares during the period. Corient Private Wealth LLC’s holdings in Boston Scientific were worth $15,232,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the stock. Gitterman Wealth Management LLC increased its position in Boston Scientific by 4.4% during the 4th quarter. Gitterman Wealth Management LLC now owns 3,959 shares of the medical equipment provider’s stock valued at $354,000 after buying an additional 168 shares in the last quarter. CBIZ Investment Advisory Services LLC increased its position in Boston Scientific by 41.3% during the 4th quarter. CBIZ Investment Advisory Services LLC now owns 3,080 shares of the medical equipment provider’s stock valued at $275,000 after buying an additional 900 shares in the last quarter. one8zero8 LLC bought a new position in Boston Scientific during the 4th quarter valued at approximately $250,000. Choate Investment Advisors increased its position in Boston Scientific by 20.0% during the 4th quarter. Choate Investment Advisors now owns 4,084 shares of the medical equipment provider’s stock valued at $365,000 after buying an additional 680 shares in the last quarter. Finally, Natixis Advisors LLC increased its holdings in shares of Boston Scientific by 10.0% in the 4th quarter. Natixis Advisors LLC now owns 2,030,069 shares of the medical equipment provider’s stock worth $181,326,000 after purchasing an additional 184,264 shares in the last quarter. Institutional investors own 89.07% of the company’s stock.

Insider Activity

In other news, CFO Daniel J. Brennan sold 15,087 shares of the business’s stock in a transaction dated Wednesday, February 12th. The stock was sold at an average price of $105.07, for a total value of $1,585,191.09. Following the transaction, the chief financial officer now directly owns 241,451 shares in the company, valued at $25,369,256.57. The trade was a 5.88 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP John Bradley Sorenson sold 4,119 shares of the business’s stock in a transaction dated Thursday, January 2nd. The shares were sold at an average price of $90.02, for a total value of $370,792.38. Following the completion of the transaction, the executive vice president now owns 35,319 shares in the company, valued at $3,179,416.38. The trade was a 10.44 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 137,302 shares of company stock worth $14,319,269 over the last ninety days. Corporate insiders own 0.50% of the company’s stock.

Boston Scientific Price Performance

NYSE BSX opened at $100.77 on Thursday. The company has a market capitalization of $148.72 billion, a PE ratio of 80.62, a price-to-earnings-growth ratio of 2.79 and a beta of 0.77. The company has a debt-to-equity ratio of 0.41, a quick ratio of 1.02 and a current ratio of 1.08. The business’s fifty day moving average is $101.45 and its 200 day moving average is $92.15. Boston Scientific Co. has a fifty-two week low of $66.80 and a fifty-two week high of $107.17.

Boston Scientific (NYSE:BSX) last announced its quarterly earnings data on Wednesday, February 5th. The medical equipment provider reported $0.70 EPS for the quarter, beating the consensus estimate of $0.65 by $0.05. Boston Scientific had a return on equity of 17.80% and a net margin of 11.07%. Sell-side analysts predict that Boston Scientific Co. will post 2.85 earnings per share for the current year.

Analysts Set New Price Targets

A number of analysts have commented on the company. Barclays lifted their target price on Boston Scientific from $111.00 to $118.00 and gave the stock an “overweight” rating in a report on Monday, February 10th. Stifel Nicolaus lifted their target price on Boston Scientific from $100.00 to $115.00 and gave the stock a “buy” rating in a report on Thursday, February 6th. Raymond James lifted their target price on Boston Scientific from $119.00 to $122.00 and gave the stock a “strong-buy” rating in a report on Thursday, February 6th. JPMorgan Chase & Co. lifted their target price on Boston Scientific from $100.00 to $110.00 and gave the stock an “overweight” rating in a report on Monday, December 16th. Finally, UBS Group lifted their target price on Boston Scientific from $105.00 to $130.00 and gave the stock a “buy” rating in a report on Friday, February 7th. Two analysts have rated the stock with a hold rating, twenty-one have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $108.91.

Boston Scientific Company Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.